Latham & Watkins advises initial purchasers in Halozyme Therapeutics’ $625 million convertible notes offering

The Sponsor

Loading page...

Latham & Watkins advises initial purchasers in Halozyme Therapeutics’ $625 million convertible notes offering | The Sponsor - The Sponsor